Enliven Therapeutics, Inc. Quarterly Operating Lease, Right-of-Use Asset in USD from Q1 2021 to Q2 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of lessee's right to use underlying asset under operating lease.
Summary
Enliven Therapeutics, Inc. quarterly Operating Lease, Right-of-Use Asset history and growth rate from Q1 2021 to Q2 2024.
  • Enliven Therapeutics, Inc. Operating Lease, Right-of-Use Asset for the quarter ending June 30, 2024 was $161K, a 66.1% decline year-over-year.
Operating Lease, Right-of-Use Asset, Quarterly (USD)
Operating Lease, Right-of-Use Asset, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q2 2024 $161K -$314K -66.1% Jun 30, 2024 10-Q 2024-08-13
Q1 2024 $241K -$310K -56.3% Mar 31, 2024 10-Q 2024-05-14
Q4 2023 $320K -$306K -48.9% Dec 31, 2023 10-Q 2024-08-13
Q3 2023 $398K Sep 30, 2023 10-Q 2023-11-09
Q2 2023 $475K +$345K +265% Jun 30, 2023 10-Q 2023-08-10
Q1 2023 $551K -$1.76M -76.2% Mar 31, 2023 10-Q 2023-05-11
Q4 2022 $626K +$164K +35.5% Dec 31, 2022 10-K 2024-03-14
Q2 2022 $130K -$507K -79.6% Jun 30, 2022 10-Q 2022-08-03
Q1 2022 $2.31M +$1.62M +233% Mar 31, 2022 10-Q 2022-05-06
Q4 2021 $462K Dec 31, 2021 8-K 2023-06-23
Q3 2021 $580K Sep 30, 2021 10-Q 2021-11-09
Q2 2021 $637K Jun 30, 2021 10-Q 2021-08-06
Q1 2021 $694K Mar 31, 2021 10-Q 2021-05-11
* An asterisk sign (*) next to the value indicates that the value is likely invalid.